Remove Financial Systems Remove Pharmaceutical Remove Planning
article thumbnail

CFO Corner: Anne-Laure Autret-Cornet, OSE Immunotherapeutics

Global Finance

The uncertainty and rapid changes in the global market required quick adaptation and strategic financial planning to ensure the stability and continuity of our operations. And we have ongoing important collaborations with other companies such as Boehringer Ingelheim and Veloxis Pharmaceuticals.

CFO
article thumbnail

How High-Growth Biotech Companies Rely on Cloud-Based EPM Software

Planful

In a recent webinar, How Fast-Growing Biotech Companies Manage Corporate Performance in the Cloud , Robbie Tantoco, the Associate Director and FP&A at Keryx Biopharmaceuticals, and Robert Entwistle, the Financial Systems Manager at Sigma-Tau Pharmaceuticals, Inc had a conversation. Complex legal requirements.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Finance Operations Pros face new Excel “game changer”

The Finance Weekly

But the gold standard spreadsheet software is creaking as demands pile up on financial systems analysts, they complain. In the words of another finance operations lead at a large niche pharmaceutical company: “We have a lot of manual processes and inputting and that type of stuff which I am trying to get away from.

article thumbnail

Central Banker Report Cards 2024: The Americas

Global Finance

Wide fiscal deficits, largely financed by borrowing from the central bank, and the absence of a concrete consolidation plan are likely to continue to put pressure on reserves. This has resulted in foreign exchange rationing and the emergence of parallel-market exchange rates in the context of a stabilized currency regime.” in January.

article thumbnail

Spain: Post-Pandemic Champion

Global Finance

The pharmaceutical industry stands out as a success story. ” These advantages have attracted global pharmaceutical giants like Novartis, Roche, and AstraZeneca, to establish research centers in Spain: particularly in Madrid and Barcelona, with additional hubs in Valencia, Seville, Málaga, and Santiago de Compostela.